United States - English - NLM (National Library of Medicine)

advanced rx pharmacy of tennessee, llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium gel is indicated for the topical treatment of actinic keratoses (ak). diclofenac sodium gel is contraindicated in the following patients: • with known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product [see warnings and precautions (5.1, 5.3) and description (11)] • with the history of asthma, urticaria, or other allergic type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.1, 5.2)] • application on damaged skin resulting from any etiology, including exudative dermatitis, eczema, infected lesions, burns or wounds [see warnings and precautions (5.3)] • in the setting of coronary bypass graft (cabg) surgery [see warnings and precautions (5.4)] 8.1 pregnancy risk summary use of nsaids, including diclofenac sodium gel, can cause premature closure of the fetal ductus arteriosus and

United States - English - NLM (National Library of Medicine)

advanced rx pharmacy of tennessee, llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium topical solution is indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). diclofenac sodium topical solution is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product [see warnings and precautions (5.7, 5.9)]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8)]. - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1)]. 8.1 pregnancy risk summary use of nsaids, including diclofenac sodium topical solution, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. because of these risks, limit dose and duration of u

United States - English - NLM (National Library of Medicine)

advanced rx pharmacy of tennessee, llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium topical solution, usp is indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s) (1). diclofenac sodium topical solution, usp is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product. [see warnings and precautions (5.7, 5.9)]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8)]. - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1)]. 8.1 pregnancy pregnancy category c prior to 30 weeks gestation; category d starting 30 weeks gestation. risk summary use of nsaids, including diclofenac sodium, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of

United States - English - NLM (National Library of Medicine)

advanced rx pharmacy of tennessee, llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium is indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s) (1). diclofenac sodium is contraindicated in the following patients: · known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product. [see warnings and precautions (5.7, 5.9)]. · history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8)]. · in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1)]. 8.1 pregnancy risk summary use of nsaids, including diclofenac sodium, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. because of these risks, limit dose and duration of diclofenac sodium use between about 20 and 30 w

United States - English - NLM (National Library of Medicine)

advanced rx pharmacy of tennessee, llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in adult patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications [see warnings and precautions ( 5.3)] . diclofenac sodium and misoprostol delayed-release tablets are contraindicated in the following patients: - pregnancy. use of misoprostol, a component of diclofenac sodium and misoprostol delayed-release tablets, during pregnancy can result in maternal and fetal harm, including uterine rupture, abortion, premature birth, or birth defects [see warnings and precautions ( 5.1) and use in specific populations ( 8.1)] - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions ( 5.2)] - active gastrointestinal bleeding [see warnings and precautions ( 5.3)] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions ( 5.8, 5.9)] - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium and misoprostol, other prostaglandins, or any components of the drug product [see warnings and precautions ( 5.8, 5.10)] 8.1 pregnancy risk summary diclofenac sodium and misoprostol delayed-release tablets are contraindicated in pregnant women [see contraindications ( 4)]. if a woman becomes pregnant while taking diclofenac sodium and misoprostol delayed-release tablets, discontinue the drug and advise the woman of the potential risks to her and to a fetus. there are no adequate and well-controlled studies of diclofenac sodium and misoprostol delayed-release tablets in pregnant women; however, there is information available about the active drug components of diclofenac sodium and misoprostol delayed-release tablets, diclofenac sodium and misoprostol. administration of misoprostol to pregnant women can cause uterine rupture, abortion, premature birth, or birth defects [see warnings and precautions ( 5.1)] . congenital anomalies sometimes associated with fetal death have been reported subsequent to the unsuccessful use of misoprostol as an abortifacient, but the drug’s teratogenic mechanism has not been demonstrated. use of nsaids, including diclofenac a component of diclofenac sodium and misoprostol delayed-release tablets, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment ( see data). there are clinical considerations when misoprostol and diclofenac are used in pregnant women (see clinical considerations). in reproduction studies with pregnant rabbits, there were no skeletal or visceral malformations when the combination of diclofenac sodium and misoprostol was administered during organogenesis at doses less than the maximum recommended human doses (mrhd); however, embryotoxicity was observed at this exposure (see data). based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization. in animal studies, administration of prostaglandin synthesis inhibitors such as diclofenac, resulted in increased pre- and post-implantation loss. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. clinical considerations maternal adverse reactions misoprostol may produce uterine contractions, uterine bleeding, and expulsion of the products of conception. misoprostol has been used to ripen the cervix, to induce labor, and to treat postpartum hemorrhage, outside of its approved indication. a major adverse effect of these uses is hyperstimulation of the uterus. uterine rupture, amniotic fluid embolism, severe bleeding, shock, and maternal death have been reported when misoprostol was administered to pregnant women to induce labor to induce abortion beyond the eighth week of pregnancy. higher doses of misoprostol, including the 100 mcg tablet, may increase the risk of complications from uterine hyperstimulation. diclofenac sodium and misoprostol delayed-release tablets, which contains 200 mcg of misoprostol, is likely to have a greater risk of uterine hyperstimulation than the 100 mcg tablet of misoprostol. abortions caused by misoprostol may be incomplete. cases of amniotic fluid embolism, which resulted in maternal and fetal death, have been reported with use of misoprostol during pregnancy. severe vaginal bleeding, retained placenta, shock, and pelvic pain have also been reported. these women were administered misoprostol vaginally and/or orally over a range of doses. diclofenac sodium and misoprostol delayed-release tablets are contraindicated in pregnant women [see contraindications ( 4)]. if a woman is or becomes pregnant while taking this drug, the drug should be discontinued and the patient apprised of the potential hazard to the fetus. fetal/neonatal adverse reactions misoprostol misoprostol may endanger pregnancy (may cause abortion) and thereby cause harm to the fetus when administered to a pregnant woman. use of misoprostol for the induction of labor in the third trimester was associated with uterine hyperstimulation with resulting changes in the fetal heart rate (fetal bradycardia) and fetal death (misoprostol is not approved for this use). diclofenac sodium and misoprostol delayed-release tablets are contraindicated in pregnant women [see contraindications ( 4)]. diclofenac premature closure of fetal ductus arteriosus: nsaids, including diclofenac, can cause premature closure of the fetal ductus arteriosus at about 30 weeks gestation and later in pregnancy (see data). oligohydramnios/neonatal renal impairment: use of nsaids, including diclofenac, at about 20 weeks gestation or later in pregnancy has been associated with cases of fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment (see data). labor or delivery there are no studies on the effects of diclofenac sodium and misoprostol delayed-release tablets or diclofenac during labor or delivery. in animal studies, nsaids, including diclofenac, inhibit prostaglandin synthesis, cause delayed parturition, and increase the incidence of stillbirth. in humans, some case reports and studies have associated misoprostol with risk of stillbirth, uterine hyperstimulation, perineal tear, amniotic fluid embolism, severe bleeding, shock, uterine rupture and death. the risk of uterine rupture associated with misoprostol use in pregnancy may occur at any gestational age, and increases with advancing gestational age and with prior uterine surgery, including cesarean delivery. grand multiparity also appears to be a risk factor for uterine rupture. data human data misoprostol several reports in the literature associate the use of misoprostol during the first trimester of pregnancy with skull defects, cranial nerve palsies, facial malformations, and limb defects. diclofenac data from observational studies regarding potential embryo-fetal risks of nsaid use (including diclofenac) in the first or second trimesters of pregnancy are inconclusive. premature closure of fetal ductus arteriosus: published literature reports that the use of nsaids at about 30 weeks of gestation and later in pregnancy may cause premature closure of the fetal ductus arteriosus. oligohydramnios/neonatal renal impairment: published studies and postmarketing reports describe maternal nsaid use at about 20 weeks gestation or later in pregnancy associated with fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment. these adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after nsaid initiation. in many cases, but not all, the decrease in amniotic fluid was transient and reversible with cessation of the drug. there have been a limited number of case reports of maternal nsaid use and neonatal renal dysfunction without oligohydramnios, some of which were irreversible. some cases of neonatal renal dysfunction required treatment with invasive procedures, such as exchange transfusion or dialysis. methodological limitations of these postmarketing studies and reports include lack of a control group; limited information regarding dose, duration, and timing of drug exposure; and concomitant use of other medications. these limitations preclude establishing a reliable estimate of the risk of adverse fetal and neonatal outcomes with maternal nsaid use. because the published safety data on neonatal outcomes involved mostly preterm infants, the generalizability of certain reported risks to the full-term infant exposed to nsaids through maternal use is uncertain. animal data the reproductive and developmental effects of both the combination of diclofenac sodium and misoprostol and each component of diclofenac sodium and misoprostol delayed-release tablets alone have been studied in animals. in all studies there was no evidence of teratogenicity. in an oral teratology study in pregnant rabbits, diclofenac sodium and misoprostol delayed-release tablets was administered at dose combinations (diclofenac and misoprostol, 250:1 ratio) up to 10 mg/kg/day diclofenac sodium (120 mg/m 2/day, 0.8 times the mrhd based on body surface area) and 0.04 mg/kg/day misoprostol (0.48 mg/m 2/day, 0.8 times the mrhd based on body surface area) and there was no evidence of teratogenicity. at the high dose, there was evidence of embryotoxicity (resorption and decreased fetal body weight) and maternal toxicity (decreased food intake and weight gain). in oral teratology studies with misoprostol in pregnant rats at doses up to 1.6 mg/kg/day (9.6 mg/m 2/day, 16 times the mrhd based on body surface area) and pregnant rabbits at doses up to 1.0 mg/kg/day (12 mg/m 2/day, 20 times the mrhd based on body surface area), there was no evidence of teratogenicity. in oral teratology studies with diclofenac sodium in pregnant mice at doses up to 20 mg/kg/day (60 mg/m 2/day, 0.4 times the mrhd based on body surface area), pregnant rats at doses up to 10 mg/kg/day (60 mg/m 2/day, 0.4 times the mrhd based on body surface area) and pregnant rabbits at doses up to 10 mg/kg/day (120 mg/m 2/day, 0.8 times the mrhd based on body surface area), there was no evidence of teratogenicity. 8.2 lactation risk summary no lactation studies have been conducted with diclofenac sodium and misoprostol delayed-release tablets; however, limited published literature reports that diclofenac and the active metabolite of misoprostol are present in breast milk [see clinical pharmacology ( 12.3)] . the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for diclofenac sodium and misoprostol delayed-release tablets and any potential adverse effects on the breastfed infant from the diclofenac sodium and misoprostol delayed-release tablets or from the underlying maternal condition. 8.3 females and males of reproductive potential diclofenac sodium and misoprostol delayed-release tablets are not recommended in women of childbearing potential [see warnings and precautions ( 5.1)] . if diclofenac sodium and misoprostol delayed-release tablets are prescribed, patients must be advised of the abortifacient property and warned not to give the drug to others. pregnancy testing verify pregnancy status for females of reproductive potential within 2 weeks prior to initiating diclofenac sodium and misoprostol delayed-release tablets. contraception females diclofenac sodium and misoprostol delayed-release tablets can cause fetal harm when administered to a pregnant woman [see contraindications ( 4) and use in specific populations ( 8.1)]. advise females of reproductive potential to use effective contraception during treatment with diclofenac sodium and misoprostol delayed-release tablets. diclofenac sodium and misoprostol delayed-release tablets may be prescribed if the patient: has had a negative serum pregnancy test within 2 weeks prior to beginning therapy. is capable of complying with effective contraceptive measures. has received both oral and written warnings of the hazards of misoprostol, the risk of possible contraception failure, and the danger to other women of childbearing potential should the drug be taken by mistake. will begin diclofenac sodium and misoprostol delayed-release tablets only on the second or third day of the next normal menstrual period . advise females to inform their healthcare provider of a known or suspected pregnancy. infertility females based on the mechanism of action, the use of prostaglandin-mediated nsaids, including diclofenac, a component of diclofenac sodium and misoprostol delayed-release tablets, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women [see clinical pharmacology ( 12.1)]. published animal studies have shown that administration of prostaglandin synthesis inhibitors has the potential to disrupt prostaglandin-mediated follicular rupture required for ovulation. small studies in women treated with nsaids have also shown a reversible delay in ovulation. consider withdrawal of nsaids, including diclofenac sodium and misoprostol delayed-release tablets, in women who have difficulties conceiving or who are undergoing investigation of infertility. 8.4 pediatric use safety and effectiveness of diclofenac sodium and misoprostol delayed-release tablets in pediatric patients have not been established. 8.5 geriatric use geriatric patients (those 65 years of age and older), compared to younger adult patients, are at greater risk for nsaid-associated serious cardiovascular, gastrointestinal, and/or renal adverse reactions [see warnings and precautions ( 5.2, 5.3, 5.7)] . in addition, the risk of diclofenac-associated adverse reactions may be greater in geriatric patients with renal impairment or those taking concomitant ace inhibitors or arbs [see drug interactions ( 7) and use in specific populations ( 8.6)] . avoid use of diclofenac sodium and misoprostol delayed-release tablets in geriatric patients with cardiovascular and/or renal risk factors. if use cannot be avoided, use the lowest recommended dosage for the shortest duration and monitor for cardiac and renal adverse reactions [see dosage and administration ( 2.1)] . monitor renal function in geriatric patients during treatment with diclofenac sodium and misoprostol delayed-release tablets, especially in patients with concomitant use of ace inhibitors or arbs . of the 2,184 patients in clinical studies with diclofenac sodium and misoprostol delayed-release tablets, 557 (25.5%) were 65 years of age and over. no overall differences in effectiveness were observed between these patients and younger adult patients, and other reported clinical experience has not identified differences in effectiveness between geriatric patients and younger adult patients, but greater sensitivity of some older individuals cannot be ruled out. no clinically meaningful differences in the pharmacokinetics of diclofenac and misoprostol were observed in geriatric patients compared to younger adult patients [see clinical pharmacology ( 12.3)]. 8.6 renal impairment diclofenac and misoprostol are primarily excreted by the kidney. long-term administration of nsaids has resulted in renal toxicity. correct volume status in dehydrated or hypovolemic patients prior to initiating diclofenac sodium and misoprostol delayed-release tablets. monitor renal function, especially during concomitant use of ace inhibitors or arbs. also, monitor renal function in patients with hepatic impairment. avoid the use of diclofenac sodium and misoprostol delayed-release tablets in patients with advanced renal disease. if use cannot be avoided in patients with advanced renal disease, use the lowest dosage for the shortest duration, monitor the patient’s renal function and monitor for clinical signs of worsening renal function [ see warnings and precautions ( 5.7), drug interactions ( 7) and clinical pharmacology ( 12.3) ].

United States - English - NLM (National Library of Medicine)

advanced rx pharmacy of tennessee, llc - indomethacin (unii: xxe1cet956) (indomethacin - unii:xxe1cet956) - carefully consider the potential benefits and risks of indomethacin extended-release capsules and other treatment options before deciding to use indomethacin extended-release capsules. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). indomethacin extended-release capsules have been found effective in active stages of the following: 1. moderate to severe rheumatoid arthritis including acute flares of chronic disease. 2. moderate to severe ankylosing spondylitis. 3. moderate to severe osteoarthritis. 4. acute painful shoulder (bursitis and/or tendinitis). indomethacin extended-release capsules, usp are not recommended for the treatment of acute gouty arthritis. indomethacin may enable the reduction of steroid dosage in patients receiving steroids for the more severe forms of rheumatoid arthritis. in such instances the steroid dosage should be reduced slowly and the patients followed very closely for any possible a

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

corteva agriscience australia pty ltd - clopyralid present as the dimethylammonium salt - soluble concentrate - clopyralid present as the dimethylammonium salt pyridine active 600.0 g/l - herbicide - barley | barley - prior to sowing | canola oilseed crop | fallow crop land weed control | forest | industrial land or area | oat - californian thistle | cape ivy | capeweed | creeping/russian knapweed,hardhead | groundsel bush | nodding thistle | prickly lettuce | saffron thistle | scotch thistle | silver wattle | skeleton weed | slender, shore or sheep thistle | soldier thistle | spear or black thistle | stemless thistle | variegated thistle | volunteer chickpea | volunteer faba bean | volunteer field pea | volunteer lentil | volunteer lucerne - seedling | volunteer lupin | volunteer medic | volunteer safflower | volunteer subterranean clover | volunteer vetch or tares | blessed thistle | bull thistle | cabbage thistle | canada thistle | carduus marianus | common lucerne | cotton thistle | creeping thistle | false star thistle | field pea | hardhead thistle | heraldic thistle | holy thistle | lady's thistle | lentil | milk thistle | musk thistle | perennial thistle | picnomom acarna | shore thistle | slender thistle | spear thistle | spotted thistle | st mary's thistle | stinging californian thistle | true scotch thistle | violet-flower

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

corteva agriscience australia pty ltd - fluroxypyr as the methyl heptyl ester - emulsifiable concentrate - fluroxypyr as the methyl heptyl ester pyridine-pyridinoxy active 333.0 g/l - herbicide - agricultural non-crop areas | barley | commercial/industrial land | forest - refer to label | forestry | grass pasture - establi - acacia leiocalyx (wattle) | amaranth or amaranthus | annual ground cherry | anoda weed | apple-of-peru | balsam pear | bathurst burr | bedstraw | bellvine | bellyache bush | billygoat weed or blue top | bittercress or swinecress | black bindweed | blackberry nightshade | bladder ketmia | blue billygoat weed | blue heliotrope or blue top | boggabri weed | bokhara clover | brigalow | broadleaf pepper tree | brown salwood or hickory wattle | butterfly pea | calotrope | caltrop or yellow vine | centro | chinee apple | chinese celtis | cleavers | cobbler's pegs | cockspur thorn | common morning glory | common sensitive plant | common sida | cooba | cowpea | cowvine | crofton weed | deadnettle | dock | dwarf amaranth or boggabri weed | flannel weed - sida cordifolia | fumitory | giant or black pigweed | giant sensitive plant | green amaranth | hairy wandering jew | hiptage | honey locust | lablab bean | lantana - lantana camara | limebush | madeira vine | melilotus or hexham scent | milkweed | mimosa bush | mimosa

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

kenso corporation (m) sdn. bhd. - ethephon - emulsifiable concentrate - ethephon organophosphorus active 720.0 g/l - growth regulator - apple | apple - legana | apple - stark crimson | cherry - see label for variety | cotton | delicious apple | golden delicious ap - accelerate ripening | acceleration of boll opening | advance or delay maturity (inc. rind) | advance/concentrate fruit maturity | aid complete removal of fruit from trees | aid mechanical harvesting | cane ripening | defoliation of cotton plants | early colour development | even out production cycle | fruit thinning | increase crop yield | increase fruit maturity or colour | initiate flowering in ratoon | pre-conditioning treatment | promote eveness of maturity | promote uniform nutfall | reduce size of heavy crop | stimulate flowering in following season | defoliation aid | delay ageing | delay harvest | delay maturity | fruit thinning | increased red colour

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - concentrated antigens of dichelobacter nodosus; light liquid paraffin; thiomersal - misc. vaccines or anti sera - concentrated antigens of dichelobacter nodosus vaccine-antigen/antibody active 100.0 ug/ml; light liquid paraffin ungrouped other 600.0 ul/ml; thiomersal mercury other 0.05 mg/ml - immunotherapy - lamb | sheep | ewe | hogget | lamb | ovine | ram | weaner | wether - footrot - dichelobacter nodosus